Shilpa Medicare’s European formulations revenue stood at ₹57 crore, a growth of 84% from last year led by continued portfolio expansion and market penetration. Domestic formulations business grew by 179% from last year.
Shilpa Medicare’s European formulations revenue stood at ₹57 crore, a growth of 84% from last year led by continued portfolio expansion and market penetration. Domestic formulations business grew by 179% from last year.